InGeNA welcomes our new Member-Elected Director Oliver Bonaccorso

InGeNA warmly welcomes our new Member-Elected Board Director – Oliver Bonaccorso

Oliver brings 17 years of experience in the genomics industry, having held commercial and strategic roles across the life sciences, diagnostics and pharmaceutical sectors. As the Johnson & Johnson ANZ company representative for InGeNA over the last 3 years, Oliver has collaborated closely with members, driven our strategic priorities pillar for quantifying the benefits of genomics and is part of our policy working group. He has also contributed to manuscript development and responses to government consultations.   

As the Precision Medicine and Diagnostics Lead at J&J, he collaborates with his extensive network in diagnostic pathology laboratories and technology manufacturers to ensure high quality testing is available for patients. Oliver also has a keen interest in regulatory policy and reimbursement frameworks for precision medicines to ensure equitable access to funded testing. 

He is passionate about the implementation of cutting-edge genomic technologies into clinical practice to improve diagnostic yield whilst minimising cost and accelerating time to results for patients. 

We’re excited to have Oliver on board as he brings his expertise and passion for advancing genomics to drive innovation in Australian precision medicine. Welcome, Oliver!